| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 销售原料药及普药(元) | - | - | - | - | 16,170,912.00 |
| 依达拉奉注射液(元) | - | - | - | - | 22,510,734.00 |
| 片剂产品(元) | 24,562,295.00 | 39,182,493.00 | 18,924,612.00 | 31,654,386.00 | - |
| 注射剂产品(元) | 16,589,142.00 | 18,660,533.00 | 7,607,074.00 | 38,891,872.00 | - |
| 原料药(元) | - | 2,938,301.00 | - | - | - |
| 其他(元) | 7,929.00 | 8,895,042.00 | 7,298,697.00 | 883,590.00 | - |
| 营业成本(元) | |||||
| 销售原料药及普药(元) | - | - | - | - | 15,391,402.00 |
| 依达拉奉注射液(元) | - | - | - | - | 1,158,439.00 |
| 片剂产品(元) | 12,344,753.00 | 26,918,836.00 | 14,397,894.00 | 28,207,989.00 | - |
| 注射剂产品(元) | 2,509,275.00 | 4,620,810.00 | 1,821,378.00 | 3,392,575.00 | - |
| 原料药(元) | - | 2,212,108.00 | - | - | - |
| 其他(元) | 3,156.00 | 2,816,465.00 | 197,431.00 | 132,965.00 | - |
| 毛利(元) | |||||
| 销售原料药及普药(元) | - | - | - | - | 779,510.00 |
| 依达拉奉注射液(元) | - | - | - | - | 21,352,295.00 |
| 片剂产品(元) | 12,217,542.00 | 12,263,657.00 | 4,526,718.00 | 3,446,397.00 | - |
| 注射剂产品(元) | 14,079,867.00 | 14,039,723.00 | 5,785,696.00 | 35,499,297.00 | - |
| 原料药(元) | - | 726,193.00 | - | - | - |
| 其他(元) | 4,773.00 | 6,078,577.00 | 7,101,266.00 | 750,625.00 | - |
| 毛利率(%) | |||||
| 销售原料药及普药(%) | - | - | - | - | 4.82 |
| 依达拉奉注射液(%) | - | - | - | - | 94.85 |
| 片剂产品(%) | 49.74 | 31.30 | 23.92 | 10.89 | - |
| 注射剂产品(%) | 84.87 | 75.24 | 76.06 | 91.28 | - |
| 原料药(%) | - | 24.71 | - | - | - |
| 其他(%) | 60.20 | 68.34 | 97.29 | 84.95 | - |
| 收入构成(%) | |||||
| 销售原料药及普药(%) | - | - | - | - | 41.81 |
| 依达拉奉注射液(%) | - | - | - | - | 58.19 |
| 片剂产品(%) | 59.68 | 56.23 | 55.94 | 44.32 | - |
| 注射剂产品(%) | 40.30 | 26.78 | 22.49 | 54.45 | - |
| 原料药(%) | - | 4.22 | - | - | - |
| 其他(%) | 0.02 | 12.77 | 21.57 | 1.24 | - |
| 毛利构成(%) | |||||
| 销售原料药及普药(%) | - | - | - | - | 3.52 |
| 依达拉奉注射液(%) | - | - | - | - | 96.48 |
| 片剂产品(%) | 46.45 | 37.04 | 26.00 | 8.68 | - |
| 注射剂产品(%) | 53.53 | 42.41 | 33.23 | 89.43 | - |
| 原料药(%) | - | 2.19 | - | - | - |
| 其他(%) | 0.02 | 18.36 | 40.78 | 1.89 | - |